YUNNAN BAIYAO(000538) 财经网·2025-04-01 03:13Core Viewpoint - Yunnan Baiyao reported a revenue increase of 2.36% to 40.033 billion yuan and a net profit increase of 16.02% to 4.749 billion yuan for the year 2024, driven by its four main business segments: pharmaceuticals, health products, traditional Chinese medicine resources, and Yunnan Provincial Pharmaceutical Company [1][4]. Revenue Breakdown - Total revenue for 2024 was 40.033 billion yuan, up from 39.111 billion yuan in 2023, reflecting a growth of 2.36% [1]. - Industrial sales revenue reached 14.468 billion yuan, accounting for 36.14% of total revenue, with a year-on-year increase of 5.30% [2]. - Commercial sales revenue was 25.473 billion yuan, making up 63.63% of total revenue, with a slight increase of 0.70% [2]. - Technical services revenue surged by 144.79% to 26.298 million yuan [2]. - Other business revenues, including planting and dining services, showed varied growth, with planting sales increasing by 66.66% [2]. Pharmaceuticals Segment - The pharmaceuticals segment generated 6.924 billion yuan in revenue, a year-on-year increase of 11.8%, with ten products exceeding 100 million yuan in sales [4]. - Key products like Yunnan Baiyao aerosol spray saw sales surpassing 2.1 billion yuan, growing over 26% [4]. - Other traditional Chinese medicine products also performed well, with significant growth in sales for products like Pudilan and Xuesaitong capsules [4]. Health Products Segment - The health products segment achieved revenue of 6.526 billion yuan, up 1.6%, and profit of 2.191 billion yuan, up 8.36% [5]. - The hair care product line, particularly Yangyuanqing, saw a notable sales increase of 30.3% [5]. Traditional Chinese Medicine Resources Segment - The traditional Chinese medicine resources segment reported external revenue of 1.751 billion yuan, a year-on-year increase of approximately 3.13% [5]. - The segment maintained stable supply and pricing for strategic varieties, with procurement costs decreasing by 31 million yuan [5]. Yunnan Provincial Pharmaceutical Company - The Yunnan Provincial Pharmaceutical Company achieved a main business revenue of 24.607 billion yuan, a slight increase of 0.48% [6]. - Non-pharmaceutical business areas, including medical devices and special medical foods, saw a sales increase of 14% [6]. R&D and Future Projects - The company is focusing on innovative drug development, with 25 ongoing projects and 11 major traditional Chinese medicine varieties under secondary development [8]. - The company is also advancing its pipeline for innovative drugs, particularly in nuclear medicine [8].